
    
      Patients already prescribed to receive etanercept for the first time for treatment of
      Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis according to the Summary
      of Product Characteristics (SmPC).

      Patients have been recruited sequentially based on eligibility criteria up to the number
      limit assigned to each site.
    
  